{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:30Z","timestamp":1787009970697,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dried blood spot (DBS) is an attractive matrix alternative to plasma for the measurement of antiepileptic drug concentrations with the possibility of self-sampling at home. The aim of this study was to evaluate whether DBS concentrations from a children population could be used as an alternative to plasma concentrations in a clinical routine laboratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Children with epilepsy using carbamazepine (CBZ), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA) had capillary blood collected for routine plasma analysis. DBS samples were collected by guardians or nurses, and the quality of sampling was compared between the groups. DBS samples were analyzed with liquid chromatography\u2013tandem mass spectrometry methods and plasma samples with immunochemical methods. In the comparison between DBS and plasma concentrations, previously analyzed sample data were pooled with data in this study and resulted in 190 comparison pairs. A bioanalytical cross-validation according to European Medicines Agency was performed. Clinicians evaluated the results to understand if a DBS concentration was linked to a different clinical dose recommendation for the patient in comparison with plasma concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Comparison of DBS sample quality showed that 2.3% of the capillary DBS collected by guardians were rejected and 8.0% of the capillary DBS collected by nurses. For DBS, a conversion factor of 0.85 for CBZ and 1.65 for VPA was applied for the comparison with plasma. LTG and LEV results were directly comparable. In the cross-validation, 88% of CBZ, 75% of LTG, 74% of LEV, and 94% of VPA comparisons were within 20% of the difference of the mean, although LEV had a few major differences (+31% to \u221240%). In 4 of the 190 comparisons, the clinical evaluation indicated a risk of conflicting decisions regarding the need for dose adjustment when using DBS concentrations. However, the risk of negative patient outcomes was considered negligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study demonstrates that a combination of bioanalytical cross-validation and clinical evaluation is an effective way to describe the applicability of DBS as an alternative to plasma, taking into account how therapeutic drug monitoring is used in specific patient groups. For LTG, converted CBZ and VPA, DBS is a feasible alternative for self-sampling at home. DBS for LEV can only be recommended for nonadherence queries due to the high variability of the plasma\/DBS concentration ratios.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000605","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:58:18Z","timestamp":1551207498000},"page":"509-518","source":"Crossref","is-referenced-by-count":20,"title":["Dried Blood Spot Self-Sampling by Guardians of Children With Epilepsy Is Feasible: Comparison With Plasma for Multiple Antiepileptic Drugs"],"prefix":"10.1097","volume":"41","author":[{"given":"Camilla","family":"Linder","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet;"},{"name":"Department of Clinical Pharmacology, Karolinska University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirja","family":"Neideman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sachsska Children's Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Wide","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Technology and Intervention (CLINTEC), Karolinska Institute;"},{"name":"Department of Pediatrics, Karolinska University Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"von Euler","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Karolinska University Hospital;"},{"name":"Departments of Clinical Science and Education, S\u00f6dersjukhuset and Medicine, Solna, Karolinska Institute, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars L.","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet;"},{"name":"Department of Clinical Pharmacology, Karolinska University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pohanka","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet;"},{"name":"Department of Clinical Pharmacology, Karolinska University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2015.04.008","article-title":"Dried blood spots for monitoring and individualization of antiepileptic drug treatment","volume":"75","author":"Milosheska","year":"2015","journal-title":"Eur J Pharm Sci."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2016.01.030","article-title":"Opening the toolbox of alternative sampling strategies in clinical routine: a key-role for (LC-)MS\/MS","volume":"84","author":"Velghe","year":"2016","journal-title":"Trends Analyt Chem."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4155\/bio.14.189","article-title":"Dried blood spot analysis to assess medication adherence and to inform personalization of treatment","volume":"6","author":"Tanna","year":"2014","journal-title":"Bioanalysis."},{"key":"R4-20230814","first-page":"CD003839","article-title":"Self-monitoring and self-management of oral anticoagulation: review","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/petr.12983","article-title":"Longitudinal study on the use of dried blood spots for home monitoring in children after kidney transplantation","volume":"21","author":"Al-Uzri","year":"2017","journal-title":"Pediatr Transpl."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mas.21441","article-title":"The use of mass spectrometry to analyze dried blood spots","volume":"35","author":"Wagner","year":"2016","journal-title":"Mass Spectrom Rev."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425255.2018.1414181","article-title":"Dried blood spots in therapeutic drug monitoring and toxicology","volume":"14","author":"Velghe","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1208\/s12248-014-9695-3","article-title":"Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ consortium microsampling working group","volume":"17","author":"Evans","year":"2015","journal-title":"AAPS J."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4155\/bio.11.132","article-title":"EBF recommendation on the validation of bioanalytical methods for dried blood spots","volume":"3","author":"Timmerman","year":"2011","journal-title":"Bioanalysis"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.4155\/bio.14.185","article-title":"Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review","volume":"6","author":"Jager","year":"2014","journal-title":"Bioanalysis"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1373\/clinchem.2017.275966","article-title":"State of the science in dried blood spots","volume":"64","author":"Freeman","year":"2018","journal-title":"Clin Chem."},{"key":"R17-20230814","first-page":"CD011412","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"12","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Antiepileptic drugs in epilepsy: a 2018 Update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.4155\/bio.15.99","article-title":"A LC \u2013 MS\/MS method for therapeutic drug monitoring of carbamazepine, lamotrigine and valproic acid in DBS","volume":"7","author":"Linder","year":"2015","journal-title":"Bioanalysis."},{"key":"R20-20230814","first-page":"412","article-title":"Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling","volume":"50","author":"Linder","year":"2016","journal-title":"Clin Biochem."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.4155\/bio.10.159","article-title":"Pharmacokinetic considerations as to when to use dried blood spot sampling","volume":"2","author":"Emmons","year":"2010","journal-title":"Bioanalysis."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2017.11.005","article-title":"Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation","volume":"1072","author":"Linder","year":"2018","journal-title":"J Chromatogr B."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A Concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"Lin","year":"1989","journal-title":"Biometrics."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1021\/ac5022562","article-title":"Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis","volume":"86","author":"Denniff","year":"2014","journal-title":"Anal Chem."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.4155\/bio.15.134","article-title":"A disposable sampling device to collect volume-measured DBS directly from a fingerprick onto DBS paper","volume":"7","author":"Lenk","year":"2015","journal-title":"Bioanalysis."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1021\/ac503931g","article-title":"New microfluidic-based sampling procedure for overcoming the hematocrit problem associated with dried blood spot analysis","volume":"87","author":"Leuthold","year":"2015","journal-title":"Anal Chem."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00216-018-0993-y","article-title":"Precise, accurate and user-independent blood collection system for dried blood spot sample preparation","volume":"410","author":"Neto","year":"2018","journal-title":"Anal Bioanal Chem."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00216-018-0866-4","article-title":"Volumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs","volume":"410","author":"Velghe","year":"2018","journal-title":"Anal Bioanal Chem."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpba.2015.02.045","article-title":"Therapeutic drug monitoring of carbamazepine and its metabolite in children from dried blood spots using liquid chromatography and tandem mass spectrometry","volume":"109","author":"Shokry","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"e108190","DOI":"10.1371\/journal.pone.0108190","article-title":"Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy","volume":"9","author":"Kong","year":"2014","journal-title":"PLoS One."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpba.2014.03.044","article-title":"Simple procedure for determination of valproic acid in dried blood spots by gas chromatography-mass spectrometry","volume":"96","author":"Rhoden","year":"2014","journal-title":"J Pharm Biomed Anal."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/FTD.0b013e318157032d","article-title":"Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy","volume":"29","author":"Lancelin","year":"2007","journal-title":"Ther Drug Monit."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/j.1528-1167.2006.00819.x","article-title":"In situ metabolism of levetiracetam in blood of patients with epilepsy","volume":"47","author":"Patsalos","year":"2006","journal-title":"Epilepsia."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4155\/bio.10.94","article-title":"DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors","volume":"2","author":"D'Arienzo","year":"2010","journal-title":"Bioanalysis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:20:58Z","timestamp":1692037258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000605","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}